Evoke Pharma Inc financial data

Symbol
EVOK on Nasdaq
Industry
Pharmaceutical Preparations
Location
420 Stevens Avenue, Suite 230, Solana Beach, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 145 % +23%
Quick Ratio 5.37 % -18%
Debt-to-equity 220 %
Return On Equity -122 % -103%
Return On Assets -38.1 % +58.6%
Operating Margin -50.8 % +64.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.49M shares -82.4%
Common Stock, Shares, Outstanding 1.49M shares +433%
Entity Public Float 4.6M USD -13.2%
Common Stock, Value, Issued 149 USD +432%
Weighted Average Number of Shares Outstanding, Basic 1.91M shares +584%
Weighted Average Number of Shares Outstanding, Diluted 1.91M shares +584%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 10.2M USD +97.8%
Operating Income (Loss) -5.2M USD +30%
Nonoperating Income (Expense) -312K USD +14.7%
Net Income (Loss) Attributable to Parent -5.35M USD +31.3%
Earnings Per Share, Basic -2.81 USD/shares +90%
Earnings Per Share, Diluted -2.81 USD/shares +90%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 13.6M USD +187%
Inventory, Net 445K USD -7.63%
Other Assets, Current 43.9K USD -7.65%
Assets, Current 17.2M USD +152%
Operating Lease, Right-of-Use Asset 154K USD
Other Assets, Noncurrent 6.31K USD
Assets 17.5M USD +148%
Employee-related Liabilities, Current 866K USD -34.6%
Liabilities, Current 10.4M USD +7.59%
Operating Lease, Liability, Noncurrent 101K USD
Liabilities 10.5M USD +8.63%
Retained Earnings (Accumulated Deficit) -129M USD -4.34%
Stockholders' Equity Attributable to Parent 7.04M USD
Liabilities and Equity 17.5M USD +148%

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 100M shares +100%
Common Stock, Shares, Issued 1.49M shares +433%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 13.6M USD +187%
Deferred Tax Assets, Valuation Allowance 28.2M USD -2.45%
Deferred Tax Assets, Gross 28.3M USD -2.33%
Operating Lease, Liability 160K USD
Lessee, Operating Lease, Liability, to be Paid 179K USD
Operating Lease, Liability, Current 59.5K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 80.2K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 77.9K USD +23.6%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 18.1K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 20.6K USD
Deferred Tax Assets, Operating Loss Carryforwards 25M USD +5.08%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 3.27M USD 0%
Preferred Stock, Shares Outstanding 0 shares
Interest Expense 501K USD +0.27%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%